Cryo Cell International (CCEL) EBIT Margin (2010 - 2026)

Cryo Cell International (CCEL) has 17 years of EBIT Margin data on file, last reported at 9.96% in Q1 2026.

• EBIT Margin for Q1 2026 came in at 9.96%, down 329.0% year-over-year; the trailing twelve-month figure through Feb 2026 was 0.61% (down 195.0% YoY), and the FY2025 annual result was 1.53%, down 31.0% from the prior year.
• EBIT Margin advanced to 9.96% in Q1 2026 per CCEL's latest filing, from 50.58% in the prior quarter.
• Over five years, EBIT Margin peaked at 24.29% in Q3 2025 and troughed at 205.37% in Q4 2023.
• A 5-year average of 7.18% and a median of 13.25% in 2025 frame the typical range for EBIT Margin.
• The sharpest annual moves came in 2023 and 2024: EBIT Margin plunged 16773 bps in 2023, then jumped 16781 bps in 2024.
• A 5-year view of EBIT Margin shows it stood at 37.64% in 2022, then sank by 446 bps to 205.37% in 2023, then surged by 82 bps to 37.56% in 2024, then slumped by 35 bps to 50.58% in 2025, then jumped by 120 bps to 9.96% in 2026.
• Business Quant data shows CCEL's EBIT Margin at 9.96% in Q1 2026, 50.58% in Q4 2025, and 24.29% in Q3 2025.